McKesson raises 2026 EPS guidance to $38.35–$38.85 while advancing oncology and specialty platforms

Discover key insights from McKesson’s Q2 2026 earnings call, including record growth, raised guidance, and strategic investments.

McKesson Corp (MCK) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Raised Earnings ...

McKesson Corp (MCK) reports a 10% revenue increase and raises earnings guidance, despite challenges in the medical surgical ...
Zacks.com on MSN

MCK Q2 Earnings Beat, Sales Miss, '26 EPS View Up, Stock Down

McKesson posts a strong Q2 earnings beat but a slight sales miss, lifts its 2026 EPS outlook on solid specialty and tech segment growth.

McKesson raises annual profit forecast on robust demand for specialty drugs

() -Drug distributor McKesson raised its fiscal 2026 profit forecast on Wednesday, betting on strong growth in its oncology ...
StockStory.org on MSN

McKesson (NYSE:MCK) Misses Q3 Revenue Estimates

Healthcare distributor and services company McKesson (NYSE:MCK) in Q3 CY2025, but sales rose 10.1% year on year to $103.2 ...
Zacks Investment Research on MSN

McKesson (MCK) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended September 2025, McKesson (MCK) reported revenue of $103.15 billion, up 10.1% over the same period last year. EPS came in at $9.86, compared to $7.07 in the year-ago quarter. The ...